American Lung Association Launches COPD Management Program with Pharma Backing — American Lung Association

Event summary

American Lung Association debuts free COPD management program on July 8, 2026, featuring one-on-one support from healthcare providers.
Program targets reduction in symptom severity by an average of 2.9 points on the COPD Assessment Test.
Expanding partner referral networks in states with highest COPD Medicare hospitalization rates including Alabama, Florida, and Ohio.
Supported by pharmaceutical companies Sanofi, Regeneron, AstraZeneca, and Genentech.

The big picture

The American Lung Association's new COPD management initiative addresses a significant healthcare burden, with over 16 million U.S. patients and $16,000 annual per-patient costs. The program's focus on reducing rehospitalizations aligns with broader industry efforts to lower healthcare expenses through preventive care. Pharmaceutical support suggests growing interest in integrated disease management solutions beyond drug development.

What we're watching

Program Efficacy: Whether the Lung Health Navigator program can sustain measurable improvements in COPD symptom management.
Pharma Influence: How pharmaceutical backing may shape program direction and patient access to treatments, including biologics.
Geographic Impact: The pace at which the program expands into high-hospitalization-rate states and its effect on local healthcare systems.